How to appeal a Humana bone marrow transplant (allogeneic hsct) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for bone marrow transplant (allogeneic hsct)

Cited policy: Humana Out-of-State Allogeneic HSCT Center of Excellence Access (Medicare Advantage tied to NCD 110.8.1)

Covers allo-HSCT at FACT-accredited, NCI-designated, NCCN member, CIBMTR-reporting Centers of Excellence. In-network preferred; out-of-state authorized when in-state center lacks accreditation / volume / specific donor or conditioning capability. Pre-authorization with center documentation + transplant physician evaluation.

How Humana denies bone marrow transplant (allogeneic hsct) — and how to counter it

Where Humana pushes back: 1) Out-of-state COE not in network; 2) In-state center available; 3) Travel costs excessive; 4) MA plan steerage requirements.

Counter-arguments that hold up: CMS NCD 110.8.1 — Stem Cell Transplantation — covers allo-HSCT at qualifying centers; FACT accreditation is industry standard. Volume-outcome relationship (CIBMTR / NMDP data) supports referral to high-volume centers (>50 allo-HSCTs/year). Document: in-state center is NOT FACT-accredited OR NOT NCI-designated OR does NOT offer specific donor type (Haplo / UCB / Omisirge) OR has insufficient volume for the requested indication. State insurance regulators + ERISA + Medicare Advantage rules support medically-necessary out-of-state access. Hardship transportation provisions may apply.

What Humana typically denies for bone marrow transplant (allogeneic hsct)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For bone marrow transplant (allogeneic hsct), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the bone marrow transplant (allogeneic hsct) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Allo-HSCT (MAC)
• Allo-HSCT (RIC)
• Allo-HSCT (NMA)
• MRD allo-HSCT
• MUD allo-HSCT
• Haplo allo-HSCT

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.